Tilray Receives GMP Certification

01/24/2017

Today, were pleased to announce that we have become the first licensed medical cannabis producer in North America to be GMP certified in accordance with the European Medicines Agencys good manufacturing practice (GMP) standards.

GMP certification is the most rigorous standard that manufacturers of medical products must meet in their production process. As an internationally recognized standard, GMP is designed to ensure that medicines are consistently produced and controlled with the same high levels of quality and purity.

Here at home, our GMP certification means that our Canadian patients benefit from our adherence to a standard that exceeds Health Canadas quality control requirements, a separate standard called Good Production Practices (GPP). Abroad, our certification will enable us to expand distribution of our products, including dried cannabis and extracts, to new markets around the world.

GMP certification will also allow us to continue to forge new ground in clinical research, advancing the science, safety and efficacy of medical cannabis for patients with a diverse range of conditions. Tilray is supplying pharmaceutical-grade medical cannabis products for three different clinical trials that are currently in progress in partnership with world-leading hospitals and universities:

The first trial is being conducted together with the University of British Columbia to examine the safety and tolerability of medical cannabis for Canadian military veterans suffering from PTSD.

The second trial is being conducted in partnership with the University of Sydney, Chris OBrien Lifehouse and the New South Wales government to study the safety, tolerability and efficacy of cannabinoids for chemotherapy-induced nausea and vomiting.

The third trial is examining safety and tolerability of cannabinoids in children with Dravet Syndrome (a severe form of treatment-resistant epilepsy) at Torontos Hospital for Sick Children (SickKids).

We look forward to announcing additional research partnerships in the coming year.